System for cell enrichment

• US 20070059680A1
• Filed: 09/15/2005
• Published: 03/15/2007
• Est. Priority Date: 09/15/2005
• Status: Abandoned Application

• Current Assignee: Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Mehmet Toner
• Inventors: Toner, Mehmet, Kapur, Ravi, Huang, Lotien
• Application Number:
  US11/228,462
• Publication Number:
  US 20070059680A1
• Time in Patent Office: Days
• US Class Current: 435/4
• CPC Class Codes: B01L 2200/0647 Handling flowable solids, e.g. microscopic beads, cells, particles
• CPC Class Codes: B01L 2300/0816 Cards, e.g. flat sample carriers usually with flow in two horizontal directions
• CPC Class Codes: B01L 2300/0864 comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
• CPC Class Codes: B01L 2400/0409 centrifugal forces
• CPC Class Codes: B01L 2400/0472 Diffusion
• CPC Class Codes: B01L 2400/086 using baffles or other fixed flow obstructions
• CPC Class Codes: B01L 3/502746 characterised by the means for controlling flow resistance, e.g. flow controllers, baffles B01L3/502738 takes precedence
• CPC Class Codes: B01L 3/502753 characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation separation in general B01D; microapparatus for analysis using electrophoresis G01N27/44791; sample preparation G01N1/28
• CPC Class Codes: B01L 3/502761 specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules investigating characteristics of particles G01N15/00
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: B82Y 30/00 Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: G01N 1/40 Concentrating samples
• CPC Class Codes: G01N 1/4077 by other techniques involving separation of suspended solids

Abstract

The present invention provides systems useful for the enrichment of analytes, for example, cells of selected types, including but not limited to blood cells, stem cells, and pathogens, in samples. The invention also provides methods for analyzing the condition of a patient based on characteristics identified through analysis of the analytes in case and control samples.

Claims

1. A system comprising a separation module adapted for removal of more than 99.5% of enucleated cells from a blood sample and retention of more than 99% of nucleated cells from a blood sample.

2. The system of claim 1 further comprising an analyzer fluidly coupled to said separation module adapted to analyze one or more of said nucleated cells and a database for storing analysis data.

3. A system comprising:

one or more first enrichment regions, wherein said enrichment regions comprise a two dimensional plurality of obstacles defining a first fluid flow path for a first analyte and a second fluid flow path for a second analyte wherein said first analyte and said second analyte have different hydrodynamic diameters;

an analyzer fluidly coupled to said one or more enrichment regions for obtaining data on said first analyte or said second analyte; and

a database for storing said data.

4. The system of claim 3 wherein said first analyte is selected from the group consisting of a red blood cell (RBC), a fetal RBC, a trophoblast, a fetal fibroblast, a white blood cell (WBCs), an infected WBC, a stem cell, an epithelial cell, an endothelial cell, a stem cell, a cancer cell, a viral cell, a bacterial cell, and protozoan.

5. The system of claim 3 wherein said cell type is found in vivo at a concentration of less than 1×

10<sup>−

3</sup> cells/μ

L.

6. The system of claim 3 wherein gaps between obstacles in said first enrichment region is at most 1000 microns.

7. The system of claim 3 further comprising one or more second enrichment regions comprising, wherein said second enrichment regions captures said first analyte or said second analyte, and wherein said second enrichment region is in fluid communication with said first enrichment region.

8. The system of claim 3 wherein said one or more first enrichment regions are adapted to retain at least 99% of said first analyte.

9. The system of claim 3 wherein said one or more first enrichment regions are adapted to increase concentration of said first analyte by at least a factor of 100,000.

24. The system of claim 3 wherein said obstacles deterministically direct said fluid flow for said first and second analytes.

25. The system of claim 24 wherein said array of obstacles define gaps which direct the flow of sample unequally into subsequent gaps.

10. A method for identifying a characteristic associated with a condition in a patient comprising:

obtaining a plurality of control samples;

obtaining a plurality of case samples;

applying each of said samples to a device comprising a plurality of obstacles that deflect a first analyte from said sample in a direction away from a second analyte of said blood sample wherein said first analyte and said second analyte have a different hydrodynamic diameter;

analyzing said first analyte from said samples to determine a characteristic of said first analyte; and

performing an association study based on said characteristic.

11. The method of claim 10 wherein said characteristic is the presence or absence of said first analyte.

12. The method of claim 10 wherein said characteristic is the number of said first analyte.

13. The method of claim 10 wherein said characteristic is the morphology of said first analyte.

14. The method of claim 10 wherein said characteristic is the genotype of said first analyte.

15. The method of claim 10 wherein said characteristic is the proteome of said first analyte.

16. The method of claim 10 wherein said characteristic is the RNA composition of said first analyte.

17. The method of claim 10 wherein said characteristic is the level of gene expression of said first analyte.

18. The method of claim 10 wherein said plurality of control samples comprises at least 100 control samples.

19. The method of claim 10 wherein said plurality of case samples comprises at least 100 case samples.

20. The method of claim 10 wherein said control samples and case samples are blood samples.

21. The method of claim 20 wherein each blood sample comprises less than 100 mL of blood.

22. The method of claim 10 wherein said analyte is a cell type.

23. The method of claim 22 wherein said analyte is an epithelial cell, a cancer cell, or a fetal cell.